849 related articles for article (PubMed ID: 33208827)
1. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.
Kuo TY; Lin MY; Coffman RL; Campbell JD; Traquina P; Lin YJ; Liu LT; Cheng J; Wu YC; Wu CC; Tang WH; Huang CG; Tsao KC; Chen C
Sci Rep; 2020 Nov; 10(1):20085. PubMed ID: 33208827
[TBL] [Abstract][Full Text] [Related]
2. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
4. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
Liu H; Zhou C; An J; Song Y; Yu P; Li J; Gu C; Hu D; Jiang Y; Zhang L; Huang C; Zhang C; Yang Y; Zhu Q; Wang D; Liu Y; Miao C; Cao X; Ding L; Zhu Y; Zhu H; Bao L; Zhou L; Yan H; Fan J; Xu J; Hu Z; Xie Y; Liu J; Liu G
Vaccine; 2021 Nov; 39(48):7001-7011. PubMed ID: 34750014
[TBL] [Abstract][Full Text] [Related]
5. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
6. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
7. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
Kumru OS; Sanyal M; Friedland N; Hickey JM; Joshi R; Weidenbacher P; Do J; Cheng YC; Kim PS; Joshi SB; Volkin DB
Vaccine; 2023 Oct; 41(44):6502-6513. PubMed ID: 37620203
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice.
Lin HT; Chen CC; Chiao DJ; Chang TY; Chen XA; Young JJ; Kuo SC
Int J Biol Macromol; 2021 Dec; 193(Pt B):1885-1897. PubMed ID: 34774590
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
[TBL] [Abstract][Full Text] [Related]
10. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
11. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
Front Immunol; 2021; 12():803647. PubMed ID: 35095889
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
14. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N
J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
16. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
18. Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model.
Shrivastava T; Singh B; Rizvi ZA; Verma R; Goswami S; Vishwakarma P; Jakhar K; Sonar S; Mani S; Bhattacharyya S; Awasthi A; Surjit M
Front Immunol; 2021; 12():641447. PubMed ID: 34108961
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.
Lu M; Chamblee M; Zhang Y; Ye C; Dravid P; Park JG; Mahesh KC; Trivedi S; Murthy S; Sharma H; Cassady C; Chaiwatpongsakorn S; Liang X; Yount JS; Boyaka PN; Peeples ME; Martinez-Sobrido L; Kapoor A; Li J
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2110105119. PubMed ID: 35994646
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
Liao HC; Wu WL; Chiang CY; Huang MS; Shen KY; Huang YL; Wu SC; Liao CL; Chen HW; Liu SJ
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
